InvestorsHub Logo
Followers 1055
Posts 189434
Boards Moderated 1
Alias Born 06/19/2009

Re: ©PROPHETABLE post# 359

Wednesday, 09/14/2016 2:10:48 PM

Wednesday, September 14, 2016 2:10:48 PM

Post# of 3140
Agree.End-of-Phase 2 meeting with FDA and European authorities relating oral rigosertib in combination with azacitidine expected to take place anytime- 2H2016. June 13, 2016 interim Data from Fully-Enrolled Phase 2 Trial, "23 of 30 patients, or 77%, responded to treatment, and anticipate further updates to the data set," stated Steve Fruchtman, M.D., Chief Medical Officer of Onconova. "Of note, 84% of HMA-naïve patients responded to this novel combination"
http://investor.onconova.com/releasedetail.cfm?ReleaseID=975436

and there are more Catalysts till year-end.i'm staying long here.ONTX



My posts are my opinion and should not be used as investment advice. Make your own decisions in your stock trades.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ONTX News